fosdenopterin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
insecticides, anthelminthics, pesticides etc., phosphorous derivatives 5444 150829-29-1

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • fosdenopterin
  • fosdenopterin hydrobromide
  • GH-135
  • nulibry
  • ALXN1101
Fosdenopterin provides an exogenous source of cPMP. cPMP is converted to molybdopterin, which is then converted to molybdenum cofactor (MoCo) and restores molybdenum cofactor biosynthesis. In MOCD Type A, mutations in MOCS1 lead to deficient MOCS1A/B-dependent synthesis of cPMP, which subsequently results in deficient molybdenum-dependent enzyme activity (e.g., sulfite oxidase).
  • Molecular weight: 363.22
  • Formula: C10H14N5O8P
  • CLOGP: -3.17
  • LIPINSKI: 2
  • HAC: 13
  • HDO: 7
  • TPSA: 196.99
  • ALOGS: -1.52
  • ROTB: 0

  • Status: ONP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
Feb. 26, 2021 FDA ORIGIN

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC A16AX19 ALIMENTARY TRACT AND METABOLISM
OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS
OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS
Various alimentary tract and metabolism products
FDA EPC N0000193919 Cyclic Pyranopterin Monophosphate
FDA EXT N0000193920 Cyclic Pyranopterin Monophosphate

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Molybdenum cofactor deficiency type A indication 29692004




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
EQ 9.5MG BASE/VIAL NULIBRY SENTYNL THERAPS INC N214018 Feb. 26, 2021 RX POWDER INTRAVENOUS 7504095 Jan. 31, 2025 METHOD OF TREATING MOLYBDENUM COFACTOR DEFICIENCY TYPE A

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
EQ 9.5MG BASE/VIAL NULIBRY SENTYNL THERAPS INC N214018 Feb. 26, 2021 RX POWDER INTRAVENOUS Feb. 26, 2026 NEW CHEMICAL ENTITY
EQ 9.5MG BASE/VIAL NULIBRY SENTYNL THERAPS INC N214018 Feb. 26, 2021 RX POWDER INTRAVENOUS Feb. 26, 2028 INDICATED TO REDUCE THE RISK OF MORTALITY IN PATIENTS WITH MOLYBDENUM COFACTOR DEFICIENCY (MOCD) TYPE A

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Molybdenum cofactor biosynthesis protein 1 Enzyme UNKNOWN DRUG LABEL

External reference:

IDSource
D11779 KEGG_DRUG
4X7K2681Y7 UNII
C2934004 UMLSCUI
CHEMBL2338675 ChEMBL_ID
135463437 PUBCHEM_CID
DB16628 DRUGBANK_ID
CHEMBL4594300 ChEMBL_ID
2531287 RXNORM
343975 MMSL
39338 MMSL
d09717 MMSL
1149378000 SNOMEDCT_US
1153617008 SNOMEDCT_US
1179070005 SNOMEDCT_US
4040183 VANDF
018652 NDDF
018656 NDDF
C549445 MESH_SUPPLEMENTAL_RECORD_UI
11150 INN_ID
2301083-34-9 SECONDARY_CAS_RN

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Nulibry HUMAN PRESCRIPTION DRUG LABEL 1 73129-001 INJECTION, POWDER, FOR SOLUTION 9.50 mg INTRAVENOUS NDA 27 sections